Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Cancer discovery·2024
Same author

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.

Cancer discovery·2022
Same author

Structure of the human clamp loader reveals an autoinhibited conformation of a substrate-bound AAA+ switch.

Proceedings of the National Academy of Sciences of the United States of America·2020
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.8K

Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.

Anupong Tangpeerachaikul1, Scot Mente1, Joe Magrino1

  • 1Nuvalent, Inc., Cambridge, Massachusetts.

Molecular Cancer Therapeutics
|April 29, 2025
PubMed
Summary

Zidesamtinib (NVL-520) effectively inhibits over 1,500 ROS1 mutations with minimal resistance, outperforming other inhibitors. This novel drug shows promise for treating ROS1-positive cancers, including brain metastases.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K

Related Experiment Videos

Last Updated: May 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) and other cancers can be driven by ROS1 fusions.
  • Emergent resistance mutations and brain metastases pose significant challenges in ROS1-positive cancer treatment.
  • Off-target TRK inhibition by some inhibitors can cause limiting central nervous system adverse events.

Purpose of the Study:

  • To evaluate zidesamtinib (NVL-520), a novel ROS1-selective inhibitor, against ROS1 resistance mutations and brain metastases.
  • To compare zidesamtinib's efficacy and resistance profile with existing ROS1 inhibitors.
  • To elucidate the molecular mechanism behind zidesamtinib's selectivity and efficacy.

Main Methods:

  • Accelerated mutagenesis screens to assess resistance development.
  • Intracranial xenograft models to evaluate efficacy against brain metastases.
  • Co-crystal structure determination and computational modeling to understand drug-target interactions.

Main Results:

  • Zidesamtinib inhibited >1,500 ROS1 mutants with ≤1% resistance, outperforming crizotinib, entrectinib, and repotrectinib.
  • Zidesamtinib demonstrated more durable responses than repotrectinib and taletrectinib in an aggressive intracranial ROS1 G2032R xenograft model.
  • Structural analysis revealed zidesamtinib uniquely accommodates the ROS1 G2032R mutation while potentially clashing with TRK, supporting its selective design.

Conclusions:

  • Zidesamtinib exhibits potent inhibition of a broad range of ROS1 resistance mutations with minimal emergence of resistance.
  • The drug shows superior efficacy in preclinical models of brain metastases compared to other ROS1 inhibitors.
  • Zidesamtinib's selective targeting mechanism suggests potential as a best-in-class therapy for ROS1-fusion-positive cancers.